Lead plaintiffs' attorney Jonathan Orent told USA TODAY that the warning letter "gives me tremendous comfort both that we're right, but also that the government is actually now doing something about these problems." He compared the reporting failures to "the opioid days," noting that expert witnesses reviewing the case had "not seen anything quite that bad." Novo Nordisk responded that the letter "does not make any conclusions about the quality or safety of our medicines" and that the company plans to "address the requests in the warning letter expeditiously and holistically." What This Means for GLP-1 Litigation Strengthening Failure-to-Warn Claims The warning letter provides plaintiffs' attorneys with a critical piece of evidence: documentation that Novo Nordisk had institutional procedures that systematically prevented adverse events from reaching the FDA
Both can potentially lower blood sugar levels, which is mostly a theoretical concern with no published reports of problems occurring in real life
More recently, medications like semaglutide (Ozempic and Wegovy) or tirzepatide (Mounjaro or Zepbound) may result in significant weight loss
How does semaglutide protect the heart
Comparative discussions around GLP-1 medications often center on differences in efficacy, dosing convenience, and metabolic impact
Peptides for muscle growth can help preserve lean mass during weight loss, which is critical for maintaining metabolic rate
